Contributions
Abstract: P1276
Type: Poster
Abstract Category: Therapy - disease modifying - Tools for detecting therapeutic response
Introduction: The immunogenicity of interferon-beta (IFN-beta) treatment is well known. The formation of antibodies against the drug diminishes treatment efficacy. IFN-beta, which belongs to the first line MS treatments are known to decrease the relapse rate by 1/3.
Methods: The high levels of binding IFN-beta antibodies correlated well with therapeutic effectiveness and can be useful among the other parameters when considering switching. Sixteen of the Hungarian MS centres took part in the trial of detecting binding antibodies in patients treated with IFN-beta. The 289 sera samples were measured by capture ELISA assay. The blood samples were collected at the 12th and 18th month of IFN-beta treatment and in case of therapeutic inefficacy. Patients with short follow-up period (< 2 years) were excluded, and the data were calculated for the 109 remaining patients.
Results: Thirty-two percent of the patients were treatment responders in the last 2-5 years, 50.5% were non-responders and 17.5% switched to other treatment because of side effects. In 5 patients (9%) the transition to secondary progressive form was the reason of non-responsiveness. In the remaining cases disease breakthrough was responsible for treatment failure. High binding antibody level was found in 8 patients (15%) of the non-responders, all had to change treatment because of relapses.
Conclusion: Our results support the earlier finding that high levels of binding antibodies in the sera correlate well with the presence of neutralizing antibodies, which are reliable also at negative values. The method of detection of binding antibodies seems to be reliable and reproducible.
Disclosure: Cecilia Rajda received support for conference attendance and research support from Teva Magyarország Gyógyszergyár Zrt. and Merck Kft.
Tünde Csépány received speakers grant from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.
Margit Keresztes: nothing to disclose
Helga Polyák: nothing to disclose.
Adrienn Kiss: nothing to disclose.
Krisztina Bencsik received speakers grants from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.
Zoltán Szolnoki: nothing to disclose.
Lajos Tóth: nothing to disclose.
Csilla Rózsa speakers grants from Sanofi Aventis Magyarország Zrt.
Judit Semjén: nothing to disclose.
Erzsébet Bense: nothing to disclose.
Zsuzsanna Simon: nothing to disclose.
Enikő Dobos: nothing to disclose.
Nárcisz Tegze: nothing to disclose.
Gábor Jakab: nothing to diclose.
Gabriella Katona: nothing to disclose.
Zsuzsanna Lohner: nothing to disclose.Judit Füvesi: received conference travel grants by Sanofi Aventis Magyarország Zrt.
László Vécsei received speakers grants from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.
Abstract: P1276
Type: Poster
Abstract Category: Therapy - disease modifying - Tools for detecting therapeutic response
Introduction: The immunogenicity of interferon-beta (IFN-beta) treatment is well known. The formation of antibodies against the drug diminishes treatment efficacy. IFN-beta, which belongs to the first line MS treatments are known to decrease the relapse rate by 1/3.
Methods: The high levels of binding IFN-beta antibodies correlated well with therapeutic effectiveness and can be useful among the other parameters when considering switching. Sixteen of the Hungarian MS centres took part in the trial of detecting binding antibodies in patients treated with IFN-beta. The 289 sera samples were measured by capture ELISA assay. The blood samples were collected at the 12th and 18th month of IFN-beta treatment and in case of therapeutic inefficacy. Patients with short follow-up period (< 2 years) were excluded, and the data were calculated for the 109 remaining patients.
Results: Thirty-two percent of the patients were treatment responders in the last 2-5 years, 50.5% were non-responders and 17.5% switched to other treatment because of side effects. In 5 patients (9%) the transition to secondary progressive form was the reason of non-responsiveness. In the remaining cases disease breakthrough was responsible for treatment failure. High binding antibody level was found in 8 patients (15%) of the non-responders, all had to change treatment because of relapses.
Conclusion: Our results support the earlier finding that high levels of binding antibodies in the sera correlate well with the presence of neutralizing antibodies, which are reliable also at negative values. The method of detection of binding antibodies seems to be reliable and reproducible.
Disclosure: Cecilia Rajda received support for conference attendance and research support from Teva Magyarország Gyógyszergyár Zrt. and Merck Kft.
Tünde Csépány received speakers grant from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.
Margit Keresztes: nothing to disclose
Helga Polyák: nothing to disclose.
Adrienn Kiss: nothing to disclose.
Krisztina Bencsik received speakers grants from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.
Zoltán Szolnoki: nothing to disclose.
Lajos Tóth: nothing to disclose.
Csilla Rózsa speakers grants from Sanofi Aventis Magyarország Zrt.
Judit Semjén: nothing to disclose.
Erzsébet Bense: nothing to disclose.
Zsuzsanna Simon: nothing to disclose.
Enikő Dobos: nothing to disclose.
Nárcisz Tegze: nothing to disclose.
Gábor Jakab: nothing to diclose.
Gabriella Katona: nothing to disclose.
Zsuzsanna Lohner: nothing to disclose.Judit Füvesi: received conference travel grants by Sanofi Aventis Magyarország Zrt.
László Vécsei received speakers grants from Sanofi Aventis Magyarország Zrt. and Biogen Idec Kft.